A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (NCT03522246)
ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian cancer patients. Response to treatment will be analyzed based on homologous recombination (HR) status of tumor samples.
Who can join: Review the eligibility criteria below.
Location: Arizona Oncology Associates, PC - HAL — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (238 Sites)
Showing the first 25 of 238 sites.
- Arizona Oncology Associates, PC - HAL — Phoenix, Arizona
- Arizona Oncology Associates, PC - HOPE — Tucson, Arizona
- The University of Arizona Cancer Center — Tucson, Arizona
- John Muir Clinical Research Center — Concord, California
- UCLA Women's Health Clinical Research Unit — Los Angeles, California
- Kaiser Permanente Northern California — San Francisco, California
- University of Colorado Cancer Center — Aurora, Colorado
- Rocky Mountain Cancer Centers — Lakewood, Colorado
- Yale University — New Haven, Connecticut
- Florida Gynecologic Oncology — Fort Myers, Florida
- MD Anderson Cancer Center-Baptist — Jacksonville, Florida
- Baptist Health Medical Group Oncology, LLC — Miami, Florida
- Florida Hospital — Orlando, Florida
- Northside Hospital — Atlanta, Georgia
- Augusta University — Augusta, Georgia
- Rush University Medical Center — Chicago, Illinois
- Dr. Sudarshan K. Sharma, Ltd - Gynecologic Oncology — Hinsdale, Illinois
- Ferrell-Duncan Clinic — Springfield, Illinois
- Community Health Network — Indianapolis, Indiana
- University of Iowa Hospitals — Iowa City, Iowa
- University of Kansas Cancer Center — Westwood, Kansas
- University of Kentucky — Lexington, Kentucky
- Norton Cancer Institute — Louisville, Kentucky
- Ochsner Medical Center — New Orleans, Louisiana
- Maine Medical Center — Scarborough, Maine
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Epithelial Ovarian Cancer
- Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian — Chapel Hill, North Carolina
- Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) — Birmingham, Alabama
- Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) — Glendale, California
- T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors — Pittsburgh, Pennsylvania
- EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma — Seattle, Washington
Explore by condition: All Epithelial Ovarian Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.